Sample processing and its preanalytical impact on the measurement of circulating matrix metalloproteinases.
Jung K
Purpose
Conclusion
Studies (1)
Purpose
The purpose of this study was to determine the effects of anticoagulant type, presence of clot activator in the serum collection tube, and the analysis of serum versus plasma on MMP-9 concentrations in healthy individuals and those with RCC. Serum and plasma were prepared within 30 minutes of blood collection and were stored at -80 degrees C until analysis.
Summary of Findings
MMP-9 concentrations were 10 to 20-fold higher in serum, collected with or without clot activator, than in plasma, regardless of which anticoagulant was used during collection. Serum collected with clot activator had significantly higher concentrations of MMP-9 than serum collected without clot activator. The authors state that strong correlations were observed between MMP-9 concentrations in heparin, citrate, and EDTA plasma. When specimens from healthy individuals were compared with those from RCC patients, higher concentrations of MMP-9 were seen in heparin plasma from RCC patients than in heparin plasma from healthy individuals (p<0.0001), but there was no significant difference in serum MMP-9 concentrations.
Biospecimens
FluidPlasmaFluidSerumFluidBloodPreservation Types
FrozenDiagnoses
NormalNeoplasticCarcinomaPlatforms
ProteinELISAPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Preaquisition Diagnosis/ patient condition NormalRenal cell carcinomaBiospecimen Acquisition Anticoagulant Lithium heparinPotassium EDTASodium citrateBiospecimen Acquisition Type of collection container/solution Tube with clot activatorTube with no clot activatorBiospecimen Aliquots and Components Blood and blood products PlasmaSerum